Nkwocha Bernard I, Singh Meenu
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Cureus. 2023 Jul 27;15(7):e42533. doi: 10.7759/cureus.42533. eCollection 2023 Jul.
Abiraterone, an androgen biosynthesis inhibitor drug approved by the Food and Drug Administration (FDA) in 2011 for the treatment of metastatic prostate cancer, has seen an increase in prescriptions over the years, owing largely to the aging population and the association of prostate cancer with increasing age. As the rate of abiraterone prescription increases, it is important for physicians to be aware of its adverse effects profile to improve patient outcomes. This case report explains the mechanism, clinical presentation, and management of abiraterone-induced hypokalemia in a 67-year-old male with prostate cancer and highlights the importance of close monitoring and management of electrolyte levels for patients on abiraterone.
阿比特龙是一种雄激素生物合成抑制剂药物，于2011年获得美国食品药品监督管理局（FDA）批准用于治疗转移性前列腺癌。多年来，其处方量有所增加，这主要归因于人口老龄化以及前列腺癌与年龄增长的关联。随着阿比特龙处方率的上升，医生了解其不良反应情况对于改善患者预后至关重要。本病例报告阐述了一名67岁前列腺癌男性患者因阿比特龙导致低钾血症的机制、临床表现及处理方法，并强调了对使用阿比特龙的患者密切监测和管理电解质水平的重要性。
